A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Mavoglurant (Primary) ; Serotonin uptake inhibitors
  • Indications Obsessive-compulsive disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 02 Jan 2017 Primary endpoint of yale - brown obsessive compulsive scale (Y-BOCS) absolute change from baseline at week 17 has not been met, according to result published in the Advances in Therapy.
    • 02 Jan 2017 Results of interim analysis (n=50) published in the Advances in Therapy
    • 09 Jun 2016 Status changed from completed to discontinued at the time of the first Interim Analysis (IA) as the study did not meet its primary efficacy objective
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top